Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.

Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA.

Cancer Res. 2010 Nov 1;70(21):8736-47. doi: 10.1158/0008-5472.CAN-10-0902. Epub 2010 Oct 19.

2.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM.

Oncotarget. 2012 Oct;3(10):1068-111. Review.

3.

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.

Lim SY, Menzies AM, Rizos H.

Cancer. 2017 Jun 1;123(S11):2118-2129. doi: 10.1002/cncr.30435. Review.

PMID:
28543695
4.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.

Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA.

Oncotarget. 2011 Mar;2(3):135-64. Review.

5.

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM.

Oncotarget. 2012 Sep;3(9):954-87. Review.

6.

The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.

Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C.

Eur J Cancer. 2017 Mar;73:85-92. doi: 10.1016/j.ejca.2016.12.010. Epub 2017 Feb 3. Review.

PMID:
28169047
7.

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.

Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA.

Aging (Albany NY). 2011 Mar;3(3):192-222. Review.

8.

Targeting protein kinase-b3 (akt3) signaling in melanoma.

Madhunapantula SV, Robertson GP.

Expert Opin Ther Targets. 2017 Mar;21(3):273-290. doi: 10.1080/14728222.2017.1279147. Epub 2017 Jan 16. Review.

PMID:
28064546
9.

Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.

Kwong LN, Davies MA.

Clin Cancer Res. 2013 Oct 1;19(19):5310-9. doi: 10.1158/1078-0432.CCR-13-0142. Review.

10.

Main roads to melanoma.

Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA.

J Transl Med. 2009 Oct 14;7:86. doi: 10.1186/1479-5876-7-86. Review.

11.

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.

Chapman PB, Hauschild A, Sondak VK.

Am Soc Clin Oncol Educ Book. 2014:e412-21. doi: 10.14694/EdBook_AM.2014.34.e412. Review.

12.

Metabolic rewiring in melanoma.

Ratnikov BI, Scott DA, Osterman AL, Smith JW, Ronai ZA.

Oncogene. 2017 Jan 12;36(2):147-157. doi: 10.1038/onc.2016.198. Epub 2016 Jun 6. Review.

13.

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Inamdar GS, Madhunapantula SV, Robertson GP.

Biochem Pharmacol. 2010 Sep 1;80(5):624-37. doi: 10.1016/j.bcp.2010.04.029. Epub 2010 May 9. Review.

14.

Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function.

Ott PA, Bhardwaj N.

Front Immunol. 2013 Oct 28;4:346. doi: 10.3389/fimmu.2013.00346. Review.

15.

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma.

Chan XY, Singh A, Osman N, Piva TJ.

Int J Mol Sci. 2017 Jul 14;18(7). pii: E1527. doi: 10.3390/ijms18071527. Review.

16.

Emerging targeted therapies for melanoma treatment (review).

Russo A, Ficili B, Candido S, Pezzino FM, Guarneri C, Biondi A, Travali S, McCubrey JA, Spandidos DA, Libra M.

Int J Oncol. 2014 Aug;45(2):516-24. doi: 10.3892/ijo.2014.2481. Epub 2014 Jun 3. Review.

17.

The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.

Madhunapantula SV, Mosca PJ, Robertson GP.

Cancer Biol Ther. 2011 Dec 15;12(12):1032-49. doi: 10.4161/cbt.12.12.18442. Epub 2011 Dec 15. Review.

18.

Current and future trials of targeted therapies in cutaneous melanoma.

Evans MS, Madhunapantula SV, Robertson GP, Drabick JJ.

Adv Exp Med Biol. 2013;779:223-55. doi: 10.1007/978-1-4614-6176-0_10. Review.

19.

The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer.

Wellbrock C, Arozarena I.

Front Cell Dev Biol. 2016 Apr 27;4:33. doi: 10.3389/fcell.2016.00033. eCollection 2016. Review.

20.

Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility.

Marzagalli M, Montagnani Marelli M, Casati L, Fontana F, Moretti RM, Limonta P.

Front Endocrinol (Lausanne). 2016 Oct 26;7:140. eCollection 2016. Review.

Supplemental Content

Support Center